The price of Amyvid (florbetapir F-18) varies depending on the imaging center and insurance coverage. As a diagnostic agent, its cost is typically bundled into the overall price of the PET scan procedure. Patients are encouraged to inquire directly with their healthcare providers and imaging facilities for specific pricing information and to understand their insurance benefits.
What is Amyvid used for?
Amyvid is a radioactive tracer used in positron emission tomography (PET) imaging. It helps in the diagnosis of Alzheimer's disease by binding to beta-amyloid plaques in the brain [1]. The presence of these plaques is a hallmark of Alzheimer's.
How does Amyvid work?
Amyvid binds to beta-amyloid deposits in the brain. When injected, it travels to the brain and attaches to these plaques. A PET scanner then detects the radiation emitted by the tracer, creating images that highlight the distribution and density of amyloid plaques [1]. An increased accumulation of these plaques, visualized by Amyvid, is indicative of Alzheimer's disease.
When does patent exclusivity for Amyvid expire?
Information on the specific patent expiration dates for Amyvid is available through resources like DrugPatentWatch.com, which tracks drug patents and exclusivity periods [2]. Understanding patent expiry is crucial for predicting when generic or biosimilar versions might become available, potentially impacting pricing.
Who manufactures Amyvid?
Amyvid was developed and is marketed by GE Healthcare [3].
What are the alternatives to Amyvid for Alzheimer's diagnosis?
Other diagnostic tools and agents exist for assessing Alzheimer's disease. These include other amyloid PET imaging agents, such as flutemetamol (Vizamyl) and florbetaben. Lumbar puncture to analyze cerebrospinal fluid for beta-amyloid and tau proteins is another diagnostic approach. Cognitive assessments and MRI scans to evaluate brain atrophy are also part of the diagnostic process [4].
What is the clinical evidence supporting Amyvid's use?
Clinical studies have demonstrated Amyvid's ability to detect beta-amyloid plaques in the brain. In clinical trials, Amyvid imaging was compared with autopsy findings, showing that a negative scan was associated with the absence of moderate or frequent beta-amyloid plaques at autopsy [1]. This supports its utility in ruling out the presence of significant amyloid pathology.